Yahoo · Nov 6, 2026
Minerva Neurosciences: Q3 Earnings Snapshot
(AP) — Minerva Neurosciences Inc. (NERV) on Friday reported profit of $100.
NASDAQ · NERV
Healthcare · Biotechnology
$2.20
Down-$0.10 (-4.35%)
Updated Nov 17, 2026, 3:13 AM
SID Score
2.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NERV
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 16, 2026
NERV closed at $2.20 after 21 trading sessions, down 5.17% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 16, 2026 | $2.30 | $2.32 | $2.18 | $2.20 | 142.08K |
| Nov 13, 2026 | $2.38 | $2.40 | $2.26 | $2.30 | 74.57K |
| Nov 12, 2026 | $2.53 | $2.53 | $2.34 | $2.38 | 79.4K |
| Nov 11, 2026 | $2.55 | $2.58 | $2.455 | $2.56 | 95.7K |
| Nov 10, 2026 | $2.63 | $2.67 | $2.38 | $2.49 | 110.86K |
| Nov 9, 2026 | $2.42 | $2.76 | $2.26 | $2.63 | 348.31K |
| Nov 6, 2026 | $2.32 | $2.44 | $2.20 | $2.42 | 238.04K |
| Nov 5, 2026 | $2.66 | $2.66 | $2.29 | $2.30 | 182.09K |
| Nov 4, 2026 | $2.41 | $2.63 | $2.39 | $2.57 | 308.64K |
| Nov 3, 2026 | $2.37 | $2.48 | $2.29 | $2.35 | 240.55K |
| Nov 2, 2026 | $2.34 | $2.51 | $2.30 | $2.345 | 230.6K |
| Oct 30, 2026 | $2.23 | $2.32 | $1.96 | $2.32 | 394.69K |
| Oct 29, 2026 | $2.25 | $2.445 | $2.20 | $2.24 | 267.56K |
| Oct 28, 2026 | $2.23 | $2.27 | $2.12 | $2.21 | 204.4K |
| Oct 27, 2026 | $2.25 | $2.335 | $2.20 | $2.23 | 239.28K |
| Oct 26, 2026 | $2.30 | $2.35 | $2.18 | $2.20 | 173.15K |
| Oct 23, 2026 | $2.37 | $2.65 | $2.25 | $2.30 | 137.59K |
| Oct 22, 2026 | $2.39 | $2.50 | $2.37 | $2.40 | 121.14K |
| Oct 21, 2026 | $2.53 | $2.59 | $2.39 | $2.39 | 102.62K |
| Oct 20, 2026 | $2.33 | $2.59 | $2.32 | $2.53 | 194.28K |
| Oct 19, 2026 | $2.37 | $2.47 | $2.24 | $2.32 | 118.34K |
The latest Smart Investors Daily articles mentioning NERV.
Company
Market Activity
Research & News
NERV research
Company profile and research snapshot.
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | Jefferies | Buy | — |
| Apr 15, 2026 | Citizens | Market Outperform | — |
| Mar 12, 2026 | HC Wainwright & Co. | Neutral | — |
| Nov 6, 2025 | HC Wainwright & Co. | Neutral | — |
| Feb 26, 2025 | HC Wainwright & Co. | Neutral | — |
No generated briefing is available yet.
Yahoo · Nov 6, 2026
(AP) — Minerva Neurosciences Inc. (NERV) on Friday reported profit of $100.
Yahoo · Nov 6, 2026
Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Recent Schizophrenia Research article describes need to expand basic science beyond dopaminergic mechanisms and to improve clinical trial methodology for negative symptoms Roluperidone remains the only late-stage drug candidate for this high-need population Company to host in-person and virtual KOL event on November 12, 2026 at 10:00 AM ET BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE)
Benzinga · Nov 6, 2026
Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 47.22 percent increase over losses of $(0.36) per share
Yahoo · Oct 29, 2026
BURLINGTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in the 2026 Jefferies Global Healthcare Conference in London. 2026 Jefferies Global Healthcare ConferenceDates: Monday, November 16 & Tuesday, November 17, 2026 Format: Fireside chat and 1x1 meetingsFireside Chat: Monday, Novemb
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning NERV.